Safety of Everolimus With Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplants: An Analysis From the Randomized TRANSFORM Study

Tedesco-Silva, HelioHelioTedesco-SilvaPascual, JulioJulioPascualViklicky, OndrejOndrejViklickyBasic-Jukic, NikolinaNikolinaBasic-JukicCassuto, ElisabethElisabethCassutoKim, Dean YDean YKimCruzado, Josep MJosep MCruzadoSommerer, ClaudiaClaudiaSommererAdel Bakr, MohamedMohamedAdel BakrGarcia, Valter DValter DGarciaMENG-KUN TSAIet al.,et al.2023-01-172023-01-172019-090041-1337https://scholars.lib.ntu.edu.tw/handle/123456789/627354The safety profiles of standard therapy versus everolimus with reduced-exposure calcineurin inhibitor (CNI) therapy using contemporary protocols in de novo kidney transplant recipients have not been compared in detail.enWOUND-HEALING COMPLICATIONS; RENAL-TRANSPLANTATION; MYCOPHENOLIC-ACID; CYTOMEGALOVIRUS-INFECTION; MTOR INHIBITORS; RISK-FACTORS; RECIPIENTS; SIROLIMUS; TACROLIMUS; EFFICACY[SDGs]SDG3Safety of Everolimus With Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplants: An Analysis From the Randomized TRANSFORM Studyjournal article10.1097/TP.0000000000002626308015482-s2.0-85068416125WOS:000509340300037https://api.elsevier.com/content/abstract/scopus_id/85068416125